APA
Wallace D. J., Gordon C., Strand V., Hobbs K., Petri M., Kalunian K., Houssiau F., Tak P. P., Isenberg D. A., Kelley L., Kilgallen B., Barry A. N., Wegener W. A. & Goldenberg D. M. (20130903). Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. : Rheumatology (Oxford, England).
Chicago
Wallace Daniel J, Gordon Caroline, Strand Vibeke, Hobbs Kathryn, Petri Michelle, Kalunian Kenneth, Houssiau Frederic, Tak Paul P, Isenberg David A, Kelley Lexy, Kilgallen Brian, Barry Anna N, Wegener William A and Goldenberg David M. 20130903. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. : Rheumatology (Oxford, England).
Harvard
Wallace D. J., Gordon C., Strand V., Hobbs K., Petri M., Kalunian K., Houssiau F., Tak P. P., Isenberg D. A., Kelley L., Kilgallen B., Barry A. N., Wegener W. A. and Goldenberg D. M. (20130903). Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. : Rheumatology (Oxford, England).
MLA
Wallace Daniel J, Gordon Caroline, Strand Vibeke, Hobbs Kathryn, Petri Michelle, Kalunian Kenneth, Houssiau Frederic, Tak Paul P, Isenberg David A, Kelley Lexy, Kilgallen Brian, Barry Anna N, Wegener William A and Goldenberg David M. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. : Rheumatology (Oxford, England). 20130903.